Kathryn E Williams

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. doi request reprint A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation
    Hélène M Faessel
    Clinical Pharmacology, Primary Care Unit, Pfizer Inc, New London, Connecticut 06320, USA
    Clin Pharmacokinet 49:799-816. 2010
  2. ncbi request reprint A double-blind study evaluating the long-term safety of varenicline for smoking cessation
    Kathryn E Williams
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Curr Med Res Opin 23:793-801. 2007
  3. doi request reprint Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition
    Hans Rollema
    Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    Biochem Pharmacol 78:813-24. 2009
  4. ncbi request reprint Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation
    Hans Rollema
    Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    Trends Pharmacol Sci 28:316-25. 2007
  5. ncbi request reprint Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
    David Gonzales
    Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 296:47-55. 2006
  6. ncbi request reprint Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial
    Douglas E Jorenby
    University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, Madison, Wis 53711, USA
    JAMA 296:56-63. 2006
  7. ncbi request reprint Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial
    Serena Tonstad
    Department of Preventive Cardiology, Ulleval University Hospital, and University of Oslo, Oslo, Norway
    JAMA 296:64-71. 2006
  8. ncbi request reprint A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers
    Shih Tzu Tsai
    Department of Community Medicine, Buddhist Tzu Chi General Hospital and Tzu Chi University College of Medicine, Hualien, Taiwan
    Clin Ther 29:1027-39. 2007
  9. ncbi request reprint The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial
    Raymond Niaura
    Brown University, Providence, RI, USA
    Curr Med Res Opin 24:1931-41. 2008

Detail Information

Publications9

  1. doi request reprint A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation
    Hélène M Faessel
    Clinical Pharmacology, Primary Care Unit, Pfizer Inc, New London, Connecticut 06320, USA
    Clin Pharmacokinet 49:799-816. 2010
    ..In all, the predictable pharmacokinetic properties and straightforward dispositional profile of varenicline simplify its use in clinical practice...
  2. ncbi request reprint A double-blind study evaluating the long-term safety of varenicline for smoking cessation
    Kathryn E Williams
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Curr Med Res Opin 23:793-801. 2007
    ..We assessed the safety of long-term varenicline administration for smoking cessation...
  3. doi request reprint Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition
    Hans Rollema
    Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    Biochem Pharmacol 78:813-24. 2009
    ....
  4. ncbi request reprint Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation
    Hans Rollema
    Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    Trends Pharmacol Sci 28:316-25. 2007
    ....
  5. ncbi request reprint Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
    David Gonzales
    Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 296:47-55. 2006
    ..The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation...
  6. ncbi request reprint Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial
    Douglas E Jorenby
    University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, Madison, Wis 53711, USA
    JAMA 296:56-63. 2006
    ..Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine...
  7. ncbi request reprint Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial
    Serena Tonstad
    Department of Preventive Cardiology, Ulleval University Hospital, and University of Oslo, Oslo, Norway
    JAMA 296:64-71. 2006
    ..The majority of cigarette smokers who achieve abstinence relapse within the first year and require many attempts before achieving permanent abstinence. Evidence to support pharmacological treatment for relapse prevention is insufficient...
  8. ncbi request reprint A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers
    Shih Tzu Tsai
    Department of Community Medicine, Buddhist Tzu Chi General Hospital and Tzu Chi University College of Medicine, Hualien, Taiwan
    Clin Ther 29:1027-39. 2007
    ..Rates of smoking in East Asian men range from >35% to >60%, and are increasing in women and the young...
  9. ncbi request reprint The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial
    Raymond Niaura
    Brown University, Providence, RI, USA
    Curr Med Res Opin 24:1931-41. 2008
    ..To determine whether self-regulated flexible dosing with varenicline tartrate is safe and effective for smoking cessation...